Health Economics›Osteosarcoma›Neoadjuvant therapy

Neoadjuvant therapy

Osteosarcoma · 8 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
MAPI Variant #01	—	R 30 134	42d	—	—	—	—	—
M-EI Variant #01	—	R 24 181	7d	—	—	—	—	—
MA-BCD Variant #01	—	R 20 995	56d	—	—	—	—	—
Cisplatin, Epirubicin, Ifosfamide Variant #01	—	R 13 819	21d	—	—	—	—	—
M-BCD Variant #01	—	R 11 925	35d	—	—	—	—	—
MAP N/A - protocol	—	R 8 253	56d	—	—	—	—	—
Cisplatin and Doxorubicin N/A - secondary systemic drug	—	R 3 077	21d	—	—	—	—	1
MA Variant #01	—	R 1 912	28d	—	—	—	—	—

8 of 8 regimens shown